Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also shown radiosensitizing effects when combined with external beam radiation. Base...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC cancer Ročník 18; číslo 1; s. 922 - 14
Hlavní autoři:	Lindenblatt, Dennis, Terraneo, Nastassja, Pellegrini, Giovanni, Cohrs, Susan, Spycher, Philipp René, Vukovic, David, Béhé, Martin, Schibli, Roger, Grünberg, Jürgen
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 25.09.2018 BioMed Central Ltd Springer Nature B.V BMC
Témata:	177Lu-radioimmunotherapy Analysis Animals Antineoplastic Agents, Immunological - pharmacology Apoptosis Apoptosis - drug effects Apoptosis - genetics Biomedical and Life Sciences Biomedicine Cancer Cancer Research Cancer therapies Care and treatment Cell cycle Cell Line, Tumor Cell Survival - drug effects Clinical trials Cyclin-dependent kinases Cytotoxicity Deoxyribonucleic acid Disease Models, Animal DNA DNA Breaks, Double-Stranded - drug effects DNA damage DNA repair Drug therapy Enzyme inhibitors Experimental therapeutics and drug development Female Flow cytometry Growth inhibition Health aspects Health Promotion and Disease Prevention Humans Immunoconjugates - pharmacology Immunohistochemistry Kinases L1CAM Lutetium mAb chCE7 Medical prognosis Medicine/Public Health Mice MK1775 (AZD1775) Monoclonal antibodies Neural Cell Adhesion Molecule L1 - antagonists & inhibitors Oncology Ovarian cancer Ovarian carcinoma Phosphorylation Protein kinase inhibitor Protein kinase inhibitors Protein Kinase Inhibitors - pharmacology Protein kinases Proteins Pyrazoles - pharmacology Pyrimidines - pharmacology Radioimmunotherapy Radioisotopes Radioresistance Research Article Response rates Surgical Oncology Tumors Xenograft Model Antitumor Assays Xenografts Lu-radioimmunotherapy MK1775 (AZD1775) Ovarian carcinoma Protein kinase inhibitor L1CAM Combination therapy mAb chCE7 177Lu-radioimmunotherapy
ISSN:	1471-2407, 1471-2407
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!